Biocon is currently trading at Rs. 372.00, up by 0.70 points or 0.19% from its previous closing of Rs. 371.60 on the BSE.
The scrip opened at Rs. 373.20 and has touched a high and low of Rs. 374.45 and Rs. 366.10 respectively. So far 75,000 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 386.80 on 12-Nov-2013 and a 52 week low of Rs. 255.00 on 04-Mar-2013.
Last one week high and low of the scrip stood at Rs. 376.50 and Rs. 364.15 respectively. The current market cap of the company is Rs. 7,440 crore.
The promoters holding in the company stood at 60.97% while Institutions and Non-Institutions held 18.06% and 20.97% respectively.
Biocon, Asia’s leading biotechnology enterprise, has received marketing authorization from the Drugs Controller General of India (DCGI) for its biosimilar Trastuzumab being developed jointly with Mylan, for the treatment of Her 2+ metastatic breast cancer.
The regulatory approval for biosimilar Trastuzumab in India is an extremely important milestone for Biocon as it is the world's first biosimilar version of Herceptin to be brought to the market. The biosimilar Trastuzumab will be marketed in India under the brand name of CANMAb by Biocon and is expected to be available to Indian patients in Q4 FY14.
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1797.80 |
Dr. Reddys Lab | 1213.90 |
Cipla | 1486.30 |
Lupin | 2069.95 |
Zydus Lifesciences | 948.70 |
View more.. |